ARTICLE | Clinical News

Medimetriks reports Phase II data for MM36 in atopic dermatitis

November 10, 2017 9:21 PM UTC

In September, Medimetriks Pharmaceuticals Inc. (Fairfield, N.J.) reported data from the Phase II MUSE trial in 32 patients with atopic dermatitis showing that twice-daily topical MM36 improved pruritus verbal rating scale (VRS), verbal analog scale (VAS) and Eczema Area and Severity Index (EASI) scores and sleep. Specifically, MM36 led to a median time to itch improvement of 5.76 hours as reported by VRS, a 60% median reduction in pruritus by hour 4 that was sustained at day 29 as reported by VAS, a 45% median reduction in EASI score by day 8 and a 66% reduction in EASI score by day 29. On the face, head and neck, MM36 reduced median EASI score by 81% by day 29. MM36 was well tolerated with no serious adverse events reported.

The open-label, international trial enrolled pediatric and adolescent patients with predominantly moderate or severe atopic dermatitis with mean total body surface area involvement of 43.7%. The trial's primary endpoint assessed pharmacokinetics. Secondary endpoints include safety, time to itch relief, change in sleep patterns and improvement in disease severity...